<DOC>
	<DOCNO>NCT00561314</DOCNO>
	<brief_summary>RATIONALE : Highly focus ultrasound energy may able kill tumor cell heat tumor without affect surround tissue . PURPOSE : This phase II trial study side effect well highly focus ultrasound energy work treat patient localized prostate cancer .</brief_summary>
	<brief_title>High-Intensity Focused Ultrasound Ablation Treating Patients With Localized Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate feasibility , side effect profile , patient acceptability high-intensity focus ultrasound ablation patient organ-confined , MRI histologically proven adenocarcinoma prostate . Secondary - To determine effectiveness therapy via biopsy , MRI , PSA level estimate time PSA nadir , record need secondary adjuvant treatment follow therapy . OUTLINE : A probe insert rectum . High-intensity focus ultrasound ( HIFU ) energy use Sonablate system deliver prostate tissue approximately 2 hour . Patients evaluate 12-month period . Patients undergo multi-sequence MRI within 10-20 day HIFU assess extent volume tumor necrosis 6 month assess disease recurrence . Blood collect PSA level baseline 1 , 3 , 6 , 9 , 12 month . Patients also undergo transrectal ultrasound biopsy 6 month evaluate disease response . Patients complete questionnaire baseline 1 , 3 , 6 , 9 , 12 month evaluate erectile sexual function , urinary flow continence , quality-of-life .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate Lowrisk disease , define follow criterion : Gleason grade total ≤ 7 ( pattern 3+4 4+3 less acceptable ) Localized disease ( unilateral bilateral ) ( stage T2c , N0 , M0 le ) Serum PSA ≤ 15 ng/mL Prostate volume ≤ 40 cc maximum anteriorposterior length ≤ 40 mm MultisequenceMRI transperineal template 5 mmspaced biopsy perform within past 6 month All malignant area must treatable focal ablation approximately 50 % prostate tissue destroy ≥ 1 neurovascular bundle preserve No intraprostatic calcification make highintensity focus ultrasound focal area cancer untreatable No metastatic disease PATIENT CHARACTERISTICS : Life expectancy ≥ 5 year Must fit general regional anesthesia assess Consultant Anesthetist No prior rectal fistula No American Society Anesthesiology grade IIIIV No latex allergies No contraindication MRI scanning ( e.g. , severe claustrophobia , permanent cardiac pacemaker , metallic implant likely contribute significant artifact image ) No moderate severe inflammatory bowel disease PRIOR CONCURRENT THERAPY : No androgen suppression treatment within past 6 month No transurethral resection prostate laser prostatectomy within past 5 year No prior treatment ( i.e. , radiotherapy , brachytherapy , surgery , laser therapy , chemotherapy , highintensity focus ultrasound , cryosurgery , thermal therapy , microwave therapy ) prostate cancer No prior significant rectal surgery prevent insertion transrectal probe</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>sexual dysfunction</keyword>
	<keyword>urinary incontinence</keyword>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
</DOC>